Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 3/20 | 0.60 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.60 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.60 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | APEX1 | P27695 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | MMP2 | P08253 | 1/20 | 0.52 |
| ▸ | MMP12 | P39900 | 1/20 | 0.52 |
| ▸ | PTPN7 | P35236 | 4/20 | 0.50 |
| ▸ | HMGCR | P04035 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10740872 | 1.00 | FFAR1 (0.60) | FFAR1CYSLTR2CYSLTR1FFAR4TDP1 | |
| SCHEMBL11109365 | 0.86 | CYP3A4 (0.64) | FFAR1CYSLTR2CYSLTR1FFAR4TDP1 | |
| SCHEMBL10795247 | 0.86 | CYSLTR2 (0.65) | FFAR1CYSLTR2CYSLTR1FFAR4TDP1 | |
| SCHEMBL10745835 | 0.86 | CYP3A4 (0.52) | FFAR1CYSLTR2CYSLTR1FFAR4TDP1 | |
| SCHEMBL10753710 | 0.81 | CYP3A4 (0.55) | FFAR1CYSLTR2CYSLTR1FFAR4TDP1 | |
| SCHEMBL10799919 | 0.81 | CYP3A4 (0.48) | FFAR1CYSLTR2CYSLTR1FFAR4TDP1 | |
| SCHEMBL21149881 | 0.80 | CYP3A4 (0.54) | CYSLTR2CYSLTR1TDP1KDM4ELMNA | |
| SCHEMBL10744806 | 0.78 | CYSLTR2 (0.57) | FFAR1CYSLTR2CYSLTR1FFAR4TDP1 | |
| SCHEMBL10435206 | 0.78 | CYSLTR2 (0.64) | CYSLTR2CYSLTR1 | |
| SCHEMBL10743657 | 0.77 | CYP3A4 (0.60) | FFAR1CYSLTR2CYSLTR1FFAR4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1666883-A1 | Diagnostic and monitoring methods for bone loss | F. Hoffmann-La Roche AG (CH) | 2006-06-07 | — | — | EP | claimed |
| EP-1476153-A2 | METHOD OF TREATING AND PREVENTING BONE LOSS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-17 | — | — | EP | claimed |
| WO-2003066048-A2 | USE OF 15-LIPOXYGENASE INHIBITORS FOR TREATING AND PREVENTING BONE LOSS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-14 | — | — | WO | claimed |
| EP-1634618-B1 | Method for identifying compounds that increase bone mineral density | HOFFMANN LA ROCHE (CH) | 2008-02-13 | — | — | EP | disclosed |
| EP-1666883-A1 | Diagnostic and monitoring methods for bone loss | F. Hoffmann-La Roche AG (CH) | 2006-06-07 | — | — | EP | disclosed |
| US-20060079488-A1 | Methods of treating and preventing bone loss | ALLARD JOHN D | 2006-04-13 | — | — | US | disclosed |
| EP-1634618-A1 | Method for identifying compounds that increase bone mineral density | F. Hoffmann-La Roche AG (CH) | 2006-03-15 | — | — | EP | disclosed |
| EP-1476153-A2 | METHOD OF TREATING AND PREVENTING BONE LOSS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-17 | — | — | EP | disclosed |
| US-20030175680-A1 | Methods of treating and preventing bone loss | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-09-18 | — | — | US | disclosed |
| WO-2003066048-A2 | USE OF 15-LIPOXYGENASE INHIBITORS FOR TREATING AND PREVENTING BONE LOSS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079488-A1 | Methods of treating and preventing bone loss | ALOX5, SOST, ALOX15B | FFAR1 2009/4885CYSLTR2 80/4885CYSLTR1 94/4885 |
| US-20030175680-A1 | Methods of treating and preventing bone loss | ALOX5, SOST, ALOX15B | FFAR1 2009/4885CYSLTR2 80/4885CYSLTR1 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.